Tumour Ablation Market is Poised to Grow At 8.2% Till 2024

According to Data Bridge Market Research new Market report Global Tumour Ablation Market, By Type (Tumour Ablation Systems (Radio Frequency Ablation, Microwave Ablation, HIFU, Laser Ablation, Cryoablation), Image Guidance Products, Accessories), By Cancer Type (Liver, Lings, Kidney, Brain, Bone, Pancreas, Breast, Others), By End-User (Hospitals, Oncology Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Trends and Forecast to 2024”,  has accounted for USD 1.8 billion in 2016, expected to reach USD 3.5 billion by 2024, growing at a CAGR of 8.2% in the forecast period 2017 to 2024.Tumour Ablation MarketAccess Report : http://databridgemarketresearch.com/reports/global-tumour-ablation-market/

The global tumour ablation market is expected to grow, owing to factors such as rising cancer incidence, increased focus on treatment of breast cancer, better reimbursement scenarios, shift towards value based reimbursements and continuous development in ablation technology. The ablation technology has an upper edge on chemotherapy and other oncology therapeutics. However ablation technology can only be used to treat tumours with size less than 3cm, owing to the healthy tissue damage caused by it. With the advent of guidance mechanisms such as ultrasounds and MRI the accuracy of the treatment has increased significantly in the past 5 years.

The ablation technology involves no surgery, an electrode is percutaneously inserted in the cancerous tissue and with the help of thermal energy the tissue is destroyed. The precision in placement of the electrode and the controlling of the temperature can be monitored using a controller and a image guidance system. In the last decade promising results have been delivered by using ablation technology which is fuelling the growth of this market.

The trend in oncology treatment is moving towards multi-speciality tumour boards collaborating into similar treatment pathways. Professionals from interventional cardiology, surgical oncology, urology, thoracic surgeries, medical oncology, radiation oncology and, breast surgeries are collaborating using ablation technology to treat cancer. This is expected to widespread the usage of this technology and fuel the market growth in the forecast years.

Market Segmentation: Tumour Ablation Market

  • The global tumour ablation market is segmented based on product types, cancer types, end-user and geography.
  • On the basis of product type, the global tumour ablation market is segmented into microwave ablation (coretherm thermotherapy devices and prolieve thermotherapy devices), radiofrequency ablation (RFA) ((temperature controlled devices, fluid cooled, catheter manipulation systems), high intensity focused ultrasound (HIFU), laser ablation and cryoablation
  • Based on cancer types, the market is segmented into liver, lings, kidney, brain, bone, pancreas, breast, others.
  • On the basis of end user, the global tumour ablation market is segmented into hospitals, oncology clinics, others.

Geographical Segmentation: Tumour Ablation Market

Based on geography the global tumour ablation market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S., Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. In 2016, Europe is expected to dominate the market with 36.7% market share, owing to the large incidence of cancer patients in this region coupled with good reimbursements.

Company Landscape: Tumour Ablation Market

The major companies in the Global Tumour Ablation market include Galil Medical, Inc., Perseon Corporation, NeuWave Medical, Inc., Koninklijke Philips N.V., INTIO Inc., Mermaid Medical A/S, SonaCare Medical, LLC, DFINE, Inc., Misonix, Inc., BVM Medical Limited, AngioDynamics, Inc., COMSOL Inc., Boston Scientific Corporation, EDAP TMS S.A. and, HealthTronics, Inc. among other companies.